FRANK J. TAKACS, M.D.; ZYGMUNT M. TOMKIEWICZ, M.D.; JOHN P. MERRILL, M.D., F.A.C.P.
The antifungal activity of amphotericin B, a polyene antibiotic synthesized by Streptomyces nodosus, has been documented adequately since its introduction into clinical use in 1956. It has been found effective in the treatment of a variety of systemic mycoses including North and South American blastomycosis, cryptococcosis, coccidioidomycosis, histoplasmosis, sporotrichosis, aspergillosis, chromoblastomycosis, and candidiasis (1-4). Clinical effectiveness has, however, been accompanied by a variety of disturbing side effects and evidences of toxicity. At some time during treatment most patients have experienced chills, fever, anorexia, nausea, vomiting, epigastric pain, myalgia, or headache (5-7). It has been suggested that the pyrogenic activity of
Learn more about subscription options.
Register Now for a free account.
TAKACS FJ, TOMKIEWICZ ZM, MERRILL JP. Amphotericin B Nephrotoxicity with Irreversible Renal Failure. Ann Intern Med. 1963;59:716–724. doi: 10.7326/0003-4819-59-5-716
Download citation file:
Published: Ann Intern Med. 1963;59(5_Part_1):716-724.
Emergency Medicine, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only